

4 February 2021
 ASX Code: MXC
 LSE Code: MXC

MGC Pharma set to become the first medicinal cannabis company to list on the London Stock Exchange

£6.5m (~A\$12m) placement completed, led by UK institutional funds

A
S
X

R
E
L
E
A
S
E

Key Highlights:

- MGC Pharma is set to become the first medicinal cannabis related company to be admitted to the main market of the London Stock Exchange (**LSE**) through a standard listing, which is scheduled to take place on Tuesday, 9 February 2021
- MGC Pharma has secured binding commitments to raise £6.5 million (~A\$12m), before costs, through a share placement to coincide with the Company's imminent LSE listing
- Strategic placement to substantial UK institutional funds led by Premier Miton and Chelverton Asset Management, with high net worth family office and professional investor clients of London equity broker Turner Pope Investments Limited (**Turner Pope**)
- MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden MGC Pharma's international profile and specifically provide direct access to UK and European institutional and other investors, which aligns with the Company's established and future European operations
- MGC Pharma set to fast-track commencement of ArtemiC™ Phase III clinical trials upon completion of the placing and LSE Listing, to be conducted across 3 continents and over 250 patients

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, 'MGC Pharma' or 'the Company'), a European based and Australian listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce that it is now set to become the first medicinal cannabis company to be admitted to the main market of the LSE on Tuesday, 9 February 2021, following a strongly supported £6.5 million (~A\$12 million) share placement (**Placement**) led by leading UK institutional fund managers, and supported by UK family office and professional high net worth investors. The binding commitments were obtained following announcement of the Company's proposed London Stock Exchange (**LSE**) listing (refer ASX release 2 February 2021).

Placement

A total of approximately 441 million new fully paid ordinary shares (**New Shares**) will be issued under the Placement at an issue price of £0.01475 per New Share (approximately A\$0.0266), which, using current exchange rates, is a premium to the last closing share price of A\$0.026 on 1 February 2021 prior to the Company's request for a trading halt for the purposes of the capital raise.

The Placement will raise £6.5 million (~A\$12 million) before costs utilising the Company's available placement capacity pursuant to ASX Listing Rule 7.1 and 7.1A. Accordingly, no shareholder approval is required for the Placement.

Turner Pope acted as Sole and Exclusive Lead Manager and Bookrunner for the Placing, which was extremely well supported by several UK institutional fund managers, led by Premier Miton and Chelverton Asset Management, alongside other UK family offices and high net worth investors.

Use of Funds

Following completion of the Placement, the Company will have cash reserves of approximately \$12.6 million (before costs). The Company will use the net proceeds of the placing to:

- meet the costs associated with a Phase III clinical trial of ArtemiC™ planned for H1 2021;
- meet the costs associated with a Phase IIb clinical trial of CannEpil®;
- increase distribution of the Group’s product range and expansion into new key markets to drive sales growth and future revenue, including Brazil and major EU countries;
- meet the registration costs for ArtemiC™ in new markets, including Russia, the Middle East and Europe; and
- for general working capital purposes, including completing construction of the Group’s proposed manufacturing facilities in Malta.

Indicative Timetable

The timetable for the Placement is detailed in the table below. All dates are indicative and subject to change.

Event	Date
ASX announcement Placement/Trading halt lifted	4 February 2021
Scheduled LSE Admission	9 February 2021
Settlement of Placement Shares	10 February 2021

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "We are delighted that following the significant progress and achievements of our company to date, we are now placed be the first medicinal cannabis company to list on the LSE. This is something we have been working towards for over 18 months, realising our strategic ambition to be closer to our operations in Europe with greater access to key UK and European strategic investors."

"We are already seeing the benefits of this decision, with the strong show of support from a number of leading UK institutional funds and sophisticated investors for the Placing, which was significantly oversubscribed, to coincide with our LSE listing. The funds will primarily be used to support the Company’s growth ambitions and key clinical research programs for our leading products, as we continue to expand our manufacturing capabilities, increase our product range and expand into new and existing key markets."

--Ends--

Authorised for release by the Board, for further information please contact:

UK PR Tavistock – Tavistock

Charlies Vivian +44 20 7920 3150

Charles.Vivian@tavistock.co.uk

PR/IR Advisors – Media & Capital Partners

Rod Hinchcliffe (IR) +61 412 277 377

Rod.Hinchcliffe@mcpartners.com.au

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline. The most advanced of these is ArtemiC™, which recently successfully completed Phase II trials as a potential aid to the recovery of moderate COVID-19 patients.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels

